2 completed, 1 terminated. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Terminated 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow Tesevatinib: new trials by email Literature Review of Tesevatinib trials Research Report on Tesevatinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD) Tesevatinib - Polycystic Kidney, Autosomal Recessive | Phase 1 | Completed | Kadmon Corporation, LLC | 10 | 2017-08-24 | 2022-05-11 |
| Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer Tesevatinib, Trastuzumab - HER-2 Positive Breast Cancer, Metastatic Malignant Neoplasm to Brain | Phase 1 / Phase 2 | Terminated | Kadmon Corporation, LLC | 17 | 2014-05-01 | 2022-04-27 |
| A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease Tesevatinib - Polycystic Kidney, Autosomal Dominant | Phase 1 / Phase 2 | Completed | Kadmon, a Sanofi Company | 69 | 2012-10-11 | 2022-11-08 |
Brain Neoplasms (1) · Polycystic Kidney Diseases (1) · Polycystic Kidney, Autosomal Dominant (1) · Polycystic Kidney, Autosomal Recessive (1)
Kadmon Corporation, LLC (2) · Kadmon, a Sanofi Company (1)
United States (3)